Publications by authors named "Jana M Carabino"
Article Synopsis
- - Hepatitis C virus (HCV) is the most common chronic bloodborne infection in the US, and following the introduction of effective antiviral treatments in 2014, the rates of HCV testing and treatment have changed over time, particularly between 2017 and 2019.
- - The study analyzed data from two large US laboratories to investigate HCV testing rates, with findings showing a 5.7% increase in HCV screening from 2017 to 2019, while the percentage of antibody-positive individuals remained consistent around 5%.
- - Although fewer HCV RNA-positive cases were reported in 2019 compared to 2017, there was a demographic shift towards younger individuals with less fibrosis, and treatment rates
Background: Insulin glargine is the first long-acting basal insulin analogue indicated for subcutaneous administration once daily at bedtime in adults with type 1 or type 2 diabetes mellitus and pediatric patients aged > or = 6 years with type 1 diabetes. It differs in structure from native human insulin by 3 amino acids, a structural modification that provides a delayed onset of action and a constant, peakless effect that has a duration of at least 24 hours.
Objective: The goal of this article was to help determine the current place in therapy of insulin glargine by reviewing all available efficacy and tolerability data published since its introduction onto the market.